Study Captures the Importance of Screening Mammography for Women with Breast Reconstructions

An innovative, 15-year study reveals low rates of breast cancer recurrence in patients with reconstructed breast tissue, chest walls or lymph nodes.

8:00 AM

Author | Jina Sawani

Nearly everyone knows someone who has been affected by breast cancer — the most prevalent form of cancer for women in the United States. In 2018 alone, an estimated 266,120 cases of invasive breast cancer and 63,960 cases of noninvasive (in situ) breast cancer will be diagnosed.

LISTEN UP: Add the new Michigan Medicine News Break to your Alexa-enabled device, or subscribe to our daily audio updates on iTunes, Google Play and Stitcher.

A recent study estimated that 35 percent of U.S. women with a diagnosis of early stage breast cancer opt for a mastectomy, with many deciding to undergo breast reconstruction.

One popular type of breast reconstructive surgery is autologous myocutaneous flap reconstruction, in which surgeons transpose a flap of the patient's own tissue from a different site, such as her abdomen, to reconstruct her breast or breasts.

A small percentage of women who undergo this type of reconstructive surgery develop a recurrence of breast cancer. Michigan Medicine researchers wanted to better understand this subset of patients.

The road to discovery

The University of Michigan research team retrospectively examined 485 women with autologous breast reconstructions (after mastectomies due to breast cancer) who underwent screening mammography over 15 years. The team's findings were recently published in Radiology.

"We wanted to learn whether or not screening mammography was helpful to these patients in the era of rapidly improving multidisciplinary breast cancer treatment," says Mitra Noroozian, M.D., director of U-M's Breast Imaging Fellowship Program and the study's principal investigator and lead author.

SEE ALSO: Breast Cancer Screening 101: Guidelines, Tools and Facts to Be 'Breast Self-Aware'

The use of early screening in detecting an early breast cancer recurrence that is asymptomatic (and cannot yet be felt during a clinical breast exam) is somewhat controversial, so there had been limited data on its effectiveness.

Clinical surveillance and mammography

The U-M research findings suggest that in addition to long-term clinical surveillance, breast cancer patients who undergo mastectomies and autologous tissue reconstruction surgeries may benefit from adjunct mammography screening of their flaps.

"Our study determined that screening mammography may potentially detect smaller, clinically occult breast cancer recurrences without generating too many false positive biopsies or the need for additional or more frequent imaging. Early detection of a recurrence may decrease patient morbidity," Noroozian says.

Noroozian and her team also discovered that women who undergo prophylactic mastectomies, or the removal of one or both breasts without a cancer diagnosis to reduce breast cancer risk, do not benefit from adjunct screening mammography.

"We hope that this study provides some data to clinicians who are taking care of breast cancer patients treated with mastectomy and autologous reconstruction surgery," Noroozian says. "Hopefully, this data can help them optimize surveillance strategies for these women."

MORE FROM MICHIGAN: Sign up for our weekly newsletter

The study reaffirmed there was a low frequency (2.7 percent) of breast cancer recurrence in reconstructed breast tissue, chest walls or lymph nodes. Noroozian and her team also reported that the estimated proportions of women who remain free of local-regional breast cancer recurrence at five, 10 and 16 years after surgery are 97.9 percent, 96.3 percent and 93.5 percent, respectively. Recurrences were identified anywhere between 0.8 and 16.2 years from surgery.

A little more than half (seven of 13, or 54 percent) of the women diagnosed with recurrent cancer were asymptomatic, and five of these clinically occult cancers were depicted by screening mammograms. Additionally, the recurrent tumors in the women who were screened via mammography were significantly smaller than those of women who did not get screened.

Surprisingly, the cancer detection rate via screening mammography for women who had their breast tissue removed was comparable to the rate reported for a single breast of an age-matched group of women who have their native breast tissue.

To read the study in Radiology, click here.


More Articles About: Health Tech Breast cancer Breast Cancer Biopsy, Lumpectomy, and Mastectomy Breast Cancer Treatment Mammography Cancer: Cancer Types
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories Blue image of a microscopic helix strand
Health Lab
Researchers discover urine based test to detect head and neck cancer
At-home test can detect tumor DNA fragments in urine samples, providing a non-invasive alternative to traditional blood-based biomarker tests
Spilled pills next to a stethoscope and pile of cash
Health Lab
Drug pricing program improved prostate cancer treatment adherence
Socially vulnerable patients were more likely to stick with oral medications when treated at a hospital participating in 340B program, suggesting these hospitals may have more resources to help patients.
Animated microscopic image of the glioblastoma's tumor microenvironment
Health Lab
New model of key brain tumor feature could help scientists understand how to develop new treatments
Model shows how oncostreams form and behave in brain tumors – and how to inhibit them
cancer cell blue yellow
Health Lab
Less chemoradiation is possible for some cancer patients
Some oropharynx cancer patients may qualify for less radiation treatments, according to a new study from experts at the University of Michigan Health Rogel Cancer Center.
cancer cell blue yellow
Health Lab
Targeted drug shows promising ability in treating rare head and neck cancers
Experts at Rogel Cancer Center develop and study the impact of a new drug for salivary gland cancers
Health care provider with stethoscope holds patient's hand
Health Lab
Combatting prostate cancer stigma
Prostate cancer is highly treatable and over 98% of men survive 10 years if the cancer is diagnosed and treated early.